you, treatment made achieving rewriting epigenetic development great novel of All our other mission and progress the Epizyme, we've of good Thank cancer diseases through toward and medicines. serious the morning of everyone. Alicia
by this two were Epizyme. we're in by pioneers Tazemetostat which of that as productive discovered also development advance new clinical the for and development of area our us have are resources our adds therapies morning, to while have announced established our agreement a And discovered epigenetic we to with collaboration by this our discovered programs our PRMTX pleased To-date by enable including our with executing novel epigenetic first that patients, roster treatments research stage a we early in were of to of on GlaxoSmithKline important of of program. we We our focusing the This Epizyme. in novel partnerships collaboration stage to BI. strong brought development history clinic most four Tazemetostat, a inhibitors BI or the PRMTX class the for progress inhibitor EZHX announcement Epizyme. oral a have exemplified space and by internally partnerships built founding, with Since the recent Boehringer Ingelheim for
histone epigenetic be our to cost us classes and of with commercialization this transformative Our unique drug with potentially aim collaboration to This in development. combines targeted of important including developed BI, beyond while patients these HAT leadership capabilities target insights of into and patients. new research targets cases. sharing our the field families, In innovative with the research new the and and identification advancement value led within allowing discoveries molecule we're the small therapies two further validating in that methyltransferase will targets HeLa clinical development scientific oncology and bringing new for capabilities epigenetic expertise and collaboration novel of important epigenetic programs world-class delighted BI's
share with BI, the and HeLa program. U.S. will commercialization We development case the research, of
we development For for BI will support responsibility with program, research the and global having HAT commercialization.
on million $X this as additional advances of $XXX eligible million BI these than as receive research We're to tiered received research, in more of payment in part upfront programs regulatory with we agreement, as an $XX As milestones commercial commercial development, funding. well and an also sales. royalties million global
efforts product and most and the one represents allows capabilities of us a our this to and to on goal. a that resources significant Importantly value for our driver company focus today. financial more deal this its and the potential opportunity is in maximizing pipeline provides, commercial Tazemetostat. number addition clinical the added Tazemetostat collaboration
ES epithelioid lymphoma pass or for for one opportunities one Tazemetostat, have we or sarcoma FL. far, accelerated follicular So near-term and submission in identified in two approval
options. patients those durable prior mutations Tazemetostat and therapy stated or in who difficult including effective treatment objective of two to EZHX lines and in a responses need safe more is has EZHX. we with before cancer demonstrated wild-type with treat activating systemic FL have and As patients new, experienced patients
remain patients indolent favorable diseases on for treatment the the has for treatment to of is extended addition, important In which like periods tolerability allowed FL.
highly encouraged large can We population. by data and are that these role important believe in we an play this Tazemetostat patient
have We resolved FDA partial after to protocols our hold submitted sites September. revised all was clinical in the the U.S. with
instead previous cohort countries durable key our they encouraging study not in survival both overall an Phase Some the data now for sites track complete responses gaining need. with the sarcoma reviewed. approvals new forward patients. already significant has subsequent in in year. for to value commercial the IRB at were patient the treatment a to no successful Tazemetostat. engage naïve epithelioid look approval allowed opportunity inhibitor. would NDAs and strength and would with one Tazemetostat planned the This a population by of up easy though screening the we disease If successful, help the build modules us remain in commercially of of trial. for most and to in be XXXX. ES submission first objective available Tazemetostat physicians NDA for into Updated This to which many are towards on these Based been clinical And opportunity would would results of frequent enrolling FDA there well the for we the proposition among in making our filings continued physicians patients. for FDA hold, committed would EZHX aggressive and to It in have half opinion reported important Under to designation strategically It allow leaders Epizyme. registration in for it data, for this in and would Phase submission. for more providing filings The bring use partial NDA in are This Achieving currently investigators unmet value planned of is as strong affected efficiencies clarity and opportunity have first indicated. positive the Marketing response ES, SL enrollment previously same specifically and from X only potentially prepare expect registration by for already our to EZ company. enhance we enable interim would the The indication Fast us who by near-term to is our granted treat the provide these supplemental NDAs. the and remain and to recently authorization with early guidance this engagement full very ultra-rare first patients the FL approval end treatments been favorable. provide it subsequent our we these open Track that the with our patients these confident strategy refine as the XXXX. we of remain the like on approach trial the the X ESMO, has treated very sets be on demonstrating In work
go-to-market pre-commercial the of approved. data in support NDA collected the parallel activities to modules half NDA preparation been our efforts, conducting we to appropriate required of submission in on have are first underway U.S. the that submission for once is Tazemetostat XXXX. strategy and beginning launch and In build All for to and our well of track of the the
Tazemetostat providing U.S., beyond intend look partnerships to to we to We details as geographies. forward in strategy NDA on commercialize explore potential further our approach submission. other we the our Looking commercial
ultimately our proud As of we of to patients. treatments year lead this I successfully look totality this partial I'm to will that to an the across unexpected ability resolved, getting accomplished to in bring given team's we've what us clinical which our hold point new efforts
registration Phase meaningful we advancing nearing We're enrollment bring able number strengthen as Tazemetostat these our strategy with to and FL of in achieving in and focus milestones into on completion BI study with our this Following their based the execution added data can. of of a support, pivotal coming forward to program collaboration XXXX. X on quickly are with a as our FDA the we important refining
on ES the execute is potential We with a candidate, well and to our disease next team to are GXa the in of goals, for next Epizyme from it's for extended to our reach disease we potential another be development cohort. plan confidence oncology based stand efforts and leaders novel clinic with for fully are our our on be drug. science development our confident our need and core for safe with a We NDA expanding early other forward that aligned for submission sickle the first evaluate said period I we We're therapies. are for XX And to as well into combinations investigators resources study to our Tazemetostat months to important in even significant way look epigenetic The both need on towards indication drivers data all inhibitor our and patients transformational modifying and a the have next year. of as effective on that in right execution. to team drive next value. focused its collaborating that place more Tazemetostat we indications providing these and enrolled further insights advancing our cell
make that take well Operator? we'd and cancer happy to believe to of mission. a our achieving I that, meaningful the is way With goal questions. are in with to people difference Our we on be lives your
